Assessing Cold-Inducible RNA-Binding Protein Levels in Lichen Planus Patients

Assessment Of Serum And Tissue Levels Of Cold-Inducible RNA-Binding Protein In Patients With Lichen Planus

This study is trying to see if levels of a specific protein in the blood and skin can help us understand lichen planus better and how it relates to the severity of the condition.

Quick facts

• Study type: Observational
• Enrollment: 80 (estimated)
• Ages: 18 Years to 60 Years
• Sex: All
• Sponsor: Sohag University (Academic / other)
• Locations: 1 site (Sohag)
• Trial ID: NCT06260189 on ClinicalTrials.gov

What this trial studies

This observational study aims to evaluate and compare serum and tissue levels of cold-inducible RNA-binding protein (CIRP) in patients diagnosed with lichen planus (LP) and healthy controls. A total of 80 participants, including 40 patients with clinically and dermoscopically confirmed LP and 40 matched healthy individuals, will undergo blood sampling and skin biopsies. The samples will be processed to measure CIRP levels using enzyme-linked immunosorbent assay (ELISA) and histological analysis. The study seeks to understand the role of CIRP in the pathogenesis of LP and its correlation with disease severity.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-60 with clinically confirmed lichen planus who have not received treatment in the last three months.

Not a fit: Patients with other dermatological diseases or systemic illnesses that may affect CIRP levels will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide insights into the role of CIRP in lichen planus, potentially leading to new diagnostic or therapeutic strategies.

How similar studies have performed: While the specific role of CIRP in lichen planus is not extensively studied, similar investigations into CIRP in other autoimmune conditions have shown promising results.

Eligibility criteria

Inclusion Criteria:

* Patients from both sexes aged 18 - 60 years, having clinical and dermoscopic confirmed LP and did not receive any topical or systemic treatment in the last 3 months for LP.

Exclusion Criteria:

1 . Pregnancy and lactation. 2. Patients with any infections or sepsis. 3. Patients with any other dermatological diseases associated with increased CIRP levels (eg. psoriasis, vitiligo or alopecia areata).

4. Patients with systemic illness (cardiac, renal, hepatic or respiratory), malignancy, with history of connective tissue diseases or on immunosuppressive treatment.

5. Patients who received any topical or systemic treatment for LP 3 months before the study.

6. Patients with oral, nail or scalp LP.

Where this trial is running

Sohag

• Aya Ahmed Elsayed — Sohag, Egypt (Recruiting)

Study contacts

• Study coordinator: Aya A Elsayed, Msc

Conditions Assessment, Self; Lichen Planus, Cold-inducible RNA-binding protein